Postpartum Depression
Conditions
Brief summary
In this study, researchers will learn how postpartum depression symptoms may change after people first start taking zuranolone. This is a drug available for doctors to prescribe for people with postpartum depression, also known as PPD. After giving birth, people with PPD can suffer from symptoms like tiredness, sadness, and a loss of interest in their daily activities. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found in the United States using a database from Accredo Specialty Pharmacy. This will include anyone who has a new prescription for zuranolone and were pregnant in the last 12 months before joining the study. The main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be done using a questionnaire called the Edinburgh Postnatal Depression Scale, also known as the EPDS. The main question that researchers want to answer is: • Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15? Researchers will also learn about : * Changes in participants' EPDS scores at Day 3, Day 45 and Day 90 in the study * Changes in EPDS scores at Day 3, Day 15, Day 45, and Day 90 in a group of participants who have moderately severe PPD before starting zuranolone * How many participants breastfeed their babies while taking zuranolone * How many participants report not starting new medicine after finishing their zuranolone treatment The study will be done as follows: * People with PPD who get a new zuranolone prescription through Accredo Specialty Pharmacy will be contacted by email or phone to ask them about their interest in participating in the study. * Before taking their first dose of zuranolone, participants will be asked to answer written questions about their symptoms using the online EPDS survey. They will also answer other survey questions about their background, environment, and general health information. Participants must take their first dose of zuranolone within 7 days of joining the study. * Participants will then be asked to answer questions using the EPDS survey, 15 days, 45 days, and 90 days after taking the first dose of zuranolone. Some participants will also be asked to complete a survey about 3 days after starting treatment. Each survey will take about 10-15 minutes to finish.
Detailed description
The primary objective of this study is to assess the reduction in Postpartum Depression (PPD) symptoms via the Edinburgh Postnatal Depression Scale (EPDS) at Day 15 in study participants. The secondary objectives are to assess the reduction in PPD symptoms via the EPDS at Day 3 (cohort 2 only), to assess the reduction in PPD symptoms via the EPDS at Day 45 and Day 90 in study participants, reduction in PPD symptoms via the EPDS at Day 15,Day 45, and Day 90 in a subgroup of participants with moderate PPD at baseline, to assess breastfeeding status during treatment with zuranolone as reported at Day 45 and to characterize treatment usage across the 90-day period via self-reported survey questions.
Interventions
DRUGZuranolone
Administered orally
Sponsors
Biogen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Participants with a prescription for zuranolone via Accredo Specialty Pharmacy. * Recent pregnancy in the last 12 months. * Confirmed diagnosis of PPD. * Able to complete the questionnaires by themselves in English. Key
Exclusion criteria
* Prior fill of zuranolone or brexanolone in last 12 months. * Participants who have taken 1 or more doses of zuranolone at the time of study screening. * Current or history of bipolar disorder. * Failure to complete baseline (Day 0) surveys. * Declined to consent. * Pregnancy that ended more than 12 months ago. Note: Other protocol-defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Edinburgh Postnatal Depression Scale (EPDS) Score at Day 15 | Baseline (Day 0), Day 15 | EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the EPDS Score in Participants With Moderate Severity | Baseline (Day 0), Days 3 (Cohort 2 only), 15, 45 and 90 | EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms. |
| Change From Baseline in the EPDS by Baseline Severity | Baseline up to Day 90 | EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms. |
| Number of Participants With no New Initiation of Medication After Completion of Zuranolone | At Days 45 and 90 | This outcome measure will be self-reported by participants. |
| Number of Participants who Report no New Initiation of Treatment After Completion of Zuranolone by Severity | At Days 45 and 90 | This outcome measure will be self-reported by participants. |
| Number of Participants Feeding Their Baby Breastmilk as Usual While Taking Zuranolone | At Day 45 | This outcome measure will be self-reported by participants. |
| Number of Participants Achieving Remission | At Days 15, Day 45, and Day 90 | — |
| Change From Baseline in the EPDS Score | Baseline (Day 0), Days 3 (Cohort 2 only), 45 and 90 | EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms. |
| Number of Participants Achieving Remission by Baseline Severity | At Days 15, Day 45, and Day 90 | — |
Countries
United States
Contacts
CONTACTUS Biogen Clinical Trial Center
CONTACTGlobal Biogen Clinical Trial Center
STUDY_DIRECTORMedical Director
Biogen
Outcome results
None listed